克罗恩病术后:术后管理策略随时间的变化及其对长期再手术率的影响——一项回顾性多中心真实世界研究
该回顾性多中心真实世界研究纳入1980至2020年间首次行根治性回盲部切除术的657例克罗恩病患者,按手术年份分为3个队列,评估术后免疫调节剂和抗TNFα药物的使用变化及再手术率。结果显示术后5年内免疫抑制剂和抗TNFα暴露显著增加,但5年和10年累积再手术概率在各队列间无显著差异。多因素分析中,首次手术前免疫抑制剂/抗TNFα暴露与再手术风险相关(HR 9.15),术后暴露与再手术风险相关(HR 0.24),但关联效应随时间变化。
要点
- 术后5年内免疫抑制剂暴露从队列1的1.6%增至队列2的38.2%和队列3的28.0%(p<0.001)。
- 术后5年内抗TNFα暴露从队列1的0.0%增至队列2的20.7%和队列3的52.0%(p<0.001)。
- 各队列5年和10年累积再手术概率无显著差异,术后用药对长期再手术率影响有限。
核心结论
- 尽管近二十年来术后免疫调节剂和抗TNFα药物使用增加,这些策略对长期再手术率的影响有限。
研究设计与样本
- 回顾性多中心真实世界研究,纳入1980至2020年间首次行根治性回盲部切除术的657例克罗恩病患者。
- 按手术年份分为3个队列:队列1(1980-1998年;n=198)、队列2(1999-2009年;n=218)、队列3(2010-2020年;n=241)。
- 采用Kaplan-Meier生存分析估计再手术率,采用Cox比例风险回归评估临床变量与再手术时间的关联。
主要发现
- 术后5年内免疫抑制剂暴露从队列1的1.6%增至队列2的38.2%和队列3的28.0%(p<0.001)。
- 术后5年内抗TNFα暴露从队列1的0.0%增至队列2的20.7%和队列3的52.0%(p<0.001)。
- 各队列5年和10年累积再手术概率无显著差异。
- 多因素分析显示首次手术前免疫抑制剂/抗TNFα暴露与再手术风险相关(HR 9.15;95%CI 2.77-30.21),术后暴露与再手术风险相关(HR 0.24;95%CI 0.07-0.74)。
- 上述关联具有时间变化效应,分别在术后5年和2年后变得不显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few data are available addressing the impact of post-operative management of Crohn's disease (CD) on long-term clinical course. AIM: To assess the evolution of post-operative management strategies over the last 40 years and their impact on the re-operation rate of CD. METHODS: We included 657 patients with CD who had undergone their first radical ileo-caecal resection between 1980 and 2020. Three cohorts were defined according to year of surgery: cohort 1 (1980-1998; n = 198), cohort 2 (1999-2009; n = 218) and cohort 3 (2010-2020; n = 241). We estimated exposure to immunomodulators and anti-TNFα agents after surgery and rates of re-operation using Kaplan-Meier survival analyses. We used Cox proportional hazards regression to assess the association of clinical variables with time to re-operation. RESULTS: Immunosuppressants, (IMMs) and anti-TNFα exposure within 5 years after surgery increased significantly from cohort 1 to cohort 2 and cohort 3 (IMMs: 1.6%, 38.2% and 28.0%, respectively, p < 0.001; anti-TNFα: 0.0%, 20.7% and 52.0%, respectively, p < 0.001). There was no significant difference across cohorts regarding the cumulative probability of re-operation within 5 and 10 years. Multivariate analysis identified IMMs/anti-TNFα exposure before the first surgery (HR 9.15; 95% CI 2.77-30.21) and post-operatively (HR: 0.24; 95% CI 0.07-0.74) as variables associated with the risk of re-operation. However, these associations had a time-varying effect and become non-significant after 5 and 2 years after surgery, respectively. CONCLUSION: Despite increased post-operative use of IMMs and anti-TNFα agents in the last two decades, the impact of these strategies on the risk of long-term re-operation rate has been modest.
引用
- Aratari A, Scribano ML, Pugliese D, et al. Crohn's disease after surgery: Changes in post-operative management strategies over time and their impact on long-term re-operation rate-A retrospective multicentre real-world study. Aliment Pharmacol Ther. 2024. PMID: 38616417. doi:10.1111/apt.18001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。